Consanance

Executive Summary

Consonance (spelled as Consanance in slug) is a Polish medical device development company offering end-to-end services from concept to certified product, with a focus on AI/machine learning and drug delivery. Founded in 2020 and headquartered in Warsaw, the company targets both startups and established MedTech/pharma clients, providing expertise in engineering, prototyping, regulatory certification, and small-batch manufacturing. By leveraging advanced technologies, Consonance aims to build innovative, compliant medical hardware and digital health solutions, positioning itself as a versatile partner in the evolving medical device landscape. As a private, bootstrapped company with no disclosed funding, Consonance's growth depends on winning service contracts and achieving regulatory milestones. The company's competitive advantage lies in combining AI/ML capabilities with traditional medical device development, enabling faster time-to-market and differentiation. While the MedTech services market is fragmented, Consonance's early focus on niche expertise and Polish location may offer cost advantages. However, scalability is limited without external capital, and the company faces competition from larger CROs and contract manufacturers. Key near-term catalysts include securing major contracts with pharmaceutical firms, obtaining ISO 13485 certification, and launching a flagship digital health product.

Upcoming Catalysts (preview)

• Q4 2026Major pharma contract for AI-driven drug delivery device40% success
• Q3 2026ISO 13485 certification achieved70% success
• Q1 2027Launch of first proprietary digital health platform30% success